Anti-inflammatory
research compounds.
Inflammation is where a lot of the peptide research clusters, and where a lot of the overclaiming happens too. We do the opposite. We point you at what the studies actually examine and leave the conclusions to the research. Compounds studied in laboratory and animal models of pro-inflammatory cytokine modulation, melanocortin-receptor signalling, and the cellular response to inflammatory stimuli. Research-grade Cresten compounds with batch-specific COA verification.
Anti-inflammatory and cytokine modulation research.
The anti-inflammatory research category covers compounds studied in laboratory and animal models for their effects on pro-inflammatory cytokine signalling, the resolution of inflammatory responses, and modulation of immune-cell activity. The mechanisms examined include NF-kappaB pathway modulation, melanocortin-receptor signalling, mast-cell stabilization, and the cellular response to oxidative stress markers.
Research peptides in this category are studied in cell culture (cytokine release assays, NF-kappaB reporter assays, mast-cell degranulation assays) and in animal models including dextran-sulfate-sodium colitis, allergic-airway models, and tissue-injury inflammatory responses. The research framework is preclinical: the compounds in this category have been examined in animal models of inflammatory bowel conditions, allergic responses, and oxidative-stress-related cellular injury.
Cresten compounds studied in this area.
KPV
CAS 67727-97-3Lysyl-prolyl-valine tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Studied for effects on pro-inflammatory cytokine modulation in laboratory models, particularly in research on inflammatory bowel conditions.
BPC-157
CAS 137525-51-0Pentadecapeptide. While primarily studied for tissue-repair effects, the published BPC-157 research literature also includes anti-inflammatory mechanisms in laboratory models, particularly in gastrointestinal mucosa and the cellular response to chemical injury.
TB-500
CAS 77591-33-443-amino-acid peptide. Published research has examined its role in modulating inflammatory responses to tissue injury, including effects on actin sequestration in inflammatory cells and regulation of cytokine release in laboratory models.
The melanocortin research framework.
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous ligand of the melanocortin receptors. The full alpha-MSH peptide has well-documented effects on pigmentation through MC1R signalling, but published research has shown that the C-terminal tripeptide KPV retains some of the parent peptide’s anti-inflammatory effects through mechanisms that appear distinct from melanocortin-receptor activation.
The mechanisms examined in published KPV research include effects on NF-kappaB pathway activation, mast-cell stabilization, and pro-inflammatory cytokine release, particularly in laboratory models of inflammatory bowel conditions. The compound is studied as a research tool for examining the cellular pathways involved in mucosal inflammation.
Research literature indexed on this area.
Methodology and verification.
Anti-inflammatory mechanism research depends on accurate compound identity: tripeptides like KPV are sufficiently short that subtle synthesis errors can produce closely-related but pharmacologically distinct sequences. Cresten Labs publishes the LC-MS spectrum on every batch certificate to confirm exact sequence identity. The HPLC chromatogram is included on the COA, available on the relevant product page.